Renal Companies in BioPortfolio's Corporate Database - Page: 2 
Renal company data on BioPortfolio. Our corporate data records list over 50,000 company records. Here you can see the latest Renal companies that have been added to our website.
Search For More Renal Companies
If you don't find the company you're looking for in the list below, you may wish to search our extensive database for further matches: Search for More Renal Companies.
More Information about Renal on BioPortfolio
We have published hundreds of Renal news stories on BioPortfolio along with dozens of Renal Clinical Trials. In addition to the corporate data, news and clinical trials, BioPortfolio also has a large collection of PubMed Articles about Renal for you to read.
Showing "renal urinary kidney" Companies 26 to 50 of 220
myCME is published by Haymarket Media Inc. (HMI), a global publication and communications company with operations on five continents. Founded in 1957 and headquartered in the United Kingdom, HMI publishes titles in 23 languages in more than 100 nations. In the United States HMI publishes a number of healthcare journals, including MPR (primary care and spec...
Cibiem is a medical device company leveraging its proprietary, minimally invasive, catheter-based approach focused on Carotid Body Modulation⢠(CBM) for the treatment of sympathetic nervous system-mediated diseases such as hypertension, heart failure, diabetes and renal failure. Based in New York City, the company was co-founded by Mark Gelfand and Howard...
Affymax, Inc. and Takeda Pharmaceuticals U.S.A., Inc.
Affymax, Inc. is a biopharmaceutical company based in Palo Alto, California. Affymax's mission is to discover, develop and deliver innovative therapies that improve the lives of patients with kidney disease and other serious and often life-threatening illnesses.
Thrasos TherapeuticsTM is a private, clinical stage, biotherapeutics company focused on the discovery and development of targeted therapies for the prevention and treatment of kidney disease. The Company is advancing therapeutic programs, led by THR-184, for renal diseases, including acute kidney injury (AKI) and chronic kidney disease (CKD). Thrasosâ...
DaVita HealthCare Partners, a Fortune 500® company, is the parent company of DaVita and HealthCare Partners. DaVita is a leading provider of kidney care in the United States, delivering dialysis services to patients with chronic kidney failure and end stage renal disease. As of September 30, 2012, DaVita operated or provided administrative services at 1...
Affymax, Inc. & Takeda Pharmaceutical Company Limited
Affymax, Inc. is a biopharmaceutical company based in Palo Alto, California. Affymax's mission is to discover, develop and deliver innovative therapies that improve the lives of patients with kidney disease and other serious and often life-threatening illnesses. For additional information on Affymax, please visit www.affymax.com.
Opsona is a leading immunology drug development company, focused on novel therapeutic approaches to key targets of the innate immune system associated with a wide range of major human diseases, including autoimmune and inflammatory diseases, transplant rejection, cancer, diabetes, Alzheimer's disease and atherosclerosis. The company was founded in 2004...
TARIS Biomedical Inc., a specialty pharmaceutical company with deep domain expertise in therapeutics and drug-delivery, is focused on local minimally-invasive drug-device convergence products. The TARIS core technology and development efforts are being applied to disease areas with high unmet medical need in which current therapies or systemic treatments h...
DaVita Inc., a Fortune 500® company, is a leading provider of kidney care in the United States, delivering dialysis services and education to patients with chronic kidney failure and end stage renal disease. As of March 31, 2010, DaVita operated or provided administrative services at 1,544 outpatient dialysis facilities, serving approximately 119,000 pa...
Plexxikon is a leader in the structure-guided discovery and development of novel small molecule pharmaceuticals to treat human disease. The companyâs lead compound, PLX4032, is in late-stage clinical trials for the treatment of melanoma. Other clinical-stage programs include PLX5568 for the treatment of polycystic kidney disease, PLX204 for the treatment...
AlloCure is a privately held, venture-funded company focused on the treatment of kidney disease. The company has made great progress in the development of the first effective cell therapy for the treatment of kidney diseases as well as other unmet medical needs. The companyâs headquarters is located in Burlington, MA, and the company maintains facilit...
CorMedix Inc. is a pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of cardiac and renal dysfunction, also known as cardiorenal disease. CorMedixâs goal is to treat kidney disease by reducing the commonly associated cardiovascular and metabolic complications, in effect, tr...
First opened in 1885, Good Samaritan Hospital is a 408-bed tertiary care facility offering some of the most comprehensive care in Los Angeles. Good Samaritan Hospital offers Cardiology and Cardiothoracic Surgery services, Neurosciences program featuring the Gamma Knife radiosurgery, Ophthalmologic Program including Retinal Surgery, Orthopedic Surgical Prog...
With its headquarters and product development in San Diego, California, TrovaGene has focused on development of tests using its patented transrenal nucleic acid technology. Transrenal DNA (Tr-DNA) and RNA (Tr-RNA) are short nucleic acid fragments from normal cell death that cross the kidney barrier and can be detected in urine. Safe and simple urine collec...
Relypsa, Inc. is a clinical-stage biopharmaceutical company leading the discovery and development of novel non-absorbed polymeric drugs for important applications in cardiovascular and renal diseases. Relypsa's lead product candidate is RLY5016, a non-absorbed potassium binder for the treatment of hyperkalemia. Relypsa is pursuing the discovery of addition...
Stealth has a rich and promising pipeline of preclinical and clinical compounds from a unique class of short peptides (500â700 Daltons each) that target mitochondria. Published, peerâreviewed data for these compounds suggest significant in vitro and in vivo efficacy for metabolic, ophthalmologic, neurologic and cardioârenal related diseases....
Fresenius Medical Care North America
Fresenius Medical Care North America is a subsidiary of Fresenius Medical Care AG & Co. KGaA, the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 1,770,000 individuals worldwide. Through its network of 2,553 dialysis clinics in North Ameri...
Concert Pharmaceuticals is a clinical stage biotechnology company focused on applying the companyâs DCE (deuterated chemical entity) platform to create novel and differentiated small molecule drugs. Concertâs approach leverages known activity and safety of existing drugs to reduce time, risk and expense of drug research and development. The Compa...
Urigen Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for urological disorders. Urigen's two lead programs target significant unmet medical needs and major market opportunities in urology. Urigen's URG101, a proprietary combination of approved drugs that is instilled in...
Dimerix is a Perth-based drug discovery company focused on developing pharmaceutical products targeting heteromers or complexes of GPCRs. Approximately 40% of all currently marketed pharmaceutical products worldwide target GPCRs. Dimerixâ GPCR-HIT platform, originally acquired from The University of Western Australia, is based on extensive research fr...
Concert Pharmaceuticals is a clinical stage biotechnology company focused on applying the companyâs DCE Platform⢠(deuterated chemical entity platform) to create novel and differentiated small molecule drugs. Concertâs approach leverages decades of pharmaceutical and clinical experience to reduce the time, risk and expense needed to create i...
Opsona is a leading immunology drug development company, focused on novel therapeutic approaches to key targets of the innate immune system associated with a wide range of major human diseases, including autoimmune and inflammatory diseases, transplant rejection, cancer, diabetes, Alzheimer's disease and atherosclerosis. The company was founded in 2004...
Shanghai Medical Technology Co., Ltd.
Shanghai Medical is a leading provider of Hemodialysis and renal care equipment, supplies, and related support services in Eastern China. Specifically, Shanghai Medical distributes and sells Hemodialysis equipment ("HDE") which is mainly used by hospitals and medical facilities and includes machines, dialyzers, disposables and diagnostic products used in Hemodialysis, throughout the People's R...
Lectus Therapeutics Limited is a UK-based drug discovery and development company, specialising in the discovery and development of best- and first-in-class ion channel therapeutics for urinary bladder disorders, pain and angina.Lectus, which began operations in the summer of 2003, exploits the power of its proprietary functional proteomics platform, LEPTICS® (Leveraged Enabling Proteomics Technol...
MediciNova, Inc. is a development-stage biopharmaceutical company focused on acquiring, developing and commercializing high-quality small molecule therapeutics. Through strategic alliances primarily with Japanese pharmaceutical companies, MediciNova has built a diversified portfolio of drug candidates each of which we believe has broad patent protection, a well-characterized and differentiated th...
